Loading...
•
Dec 31, 2024
Rigel Q4 2024 Earnings Report
Rigel reported financial results, including sales of TAVALISSE®, REZLIDHIA®, and GAVRETO®, and provided a business update.
Key Takeaways
Rigel reported record net product sales of $144.9 million, a 39% increase compared to 2023, and generated full-year net income of more than $17 million.
Total revenues were $57.6 million, including TAVALISSE net product sales were $31.0 million, REZLIDHIA net product sales were $7.4 million, and GAVRETO net product sales were $8.1 million.
TAVALISSE net product sales grew 21% compared to the same period of 2023.
REZLIDHIA net product sales grew 92% compared to the same period of 2023.
Rigel reported net income of $14.3 million, or $0.81 basic and $0.80 diluted per share.
Forward Guidance
Rigel anticipates 2025 total revenue of approximately $200 to $210 million, and anticipates it will report positive net income for the full year 2025, while funding existing and new clinical development programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...